LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Determination of tissue distribution of potent antitumor agent ureidomustin (BO-1055) by HPLC and its pharmacokinetic application in rats.

    Chien, Shin-I / Yen, Jiin-Cherng / Kakadiya, Rajesh / Chen, Ching-Huang / Lee, Te-Chang / Su, Tsann-Long / Tsai, Tung-Hu

    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

    2013  Volume 917-918, Page(s) 62–70

    Abstract: Ureidomustin hydrochloride (BO-1055) was designed as a water-soluble nitrogen-mustard, which exhibited potent anticancer activity and was selected as a candidate for preclinical studies. However, up to date, there is rarely an easy and economic method to ...

    Abstract Ureidomustin hydrochloride (BO-1055) was designed as a water-soluble nitrogen-mustard, which exhibited potent anticancer activity and was selected as a candidate for preclinical studies. However, up to date, there is rarely an easy and economic method to quantize ureidomustin in the biological samples. The aim of this study is to develop a simple yet valid quantization method to tackle this challenge. Here we present a combined high-performance liquid chromatography with photodiode array (HPLC-PDA) method in quantizing the ureidomustin in the plasma and various organs of Sprague-Dawley rats. The method was validated in terms of precision, accuracy, and extraction recovery. Furthermore, the established method was applied to study pharmacokinetics of ureidomustin in the rat's plasma and verified via a liquid chromatography tandem mass spectrometry (LC-MS/MS) method. Calibration curves of the plasma and organ samples were falling at the range between 0.5-50μg/mL and 0.1-50μg/mL (r(2)≥0.999 and CV≤±15%), respectively. The limits of detection (LOD) were 0.1μg/mL for plasma samples and 0.05μg/mL for organ samples, while the detection limits of quantification (LOQ) were 0.5μg/mL for plasma samples and 0.1μg/mL for organ samples. The average recovery of ureidomustin was about 83%. These results demonstrated a linear pharmacokinetic pattern at dosages of 10 and 30mg/kg. The pharmacokinetic data revealed that ureidomustin was best fitted to a two-compartment model with a rapid distribution phase and a slow elimination phase. Besides, after a short intravenous administration time at the dose of 10mg/kg, ureidomustin was found to be quickly distributed to all organs in rats, accumulated mainly in the kidney, and only a limited amount was detected in the brain.
    MeSH term(s) Animals ; Antineoplastic Agents/blood ; Antineoplastic Agents/chemistry ; Antineoplastic Agents/pharmacokinetics ; Chromatography, High Pressure Liquid/methods ; Limit of Detection ; Male ; Nitrogen Mustard Compounds/blood ; Nitrogen Mustard Compounds/chemistry ; Nitrogen Mustard Compounds/pharmacokinetics ; Phenylurea Compounds/blood ; Phenylurea Compounds/chemistry ; Phenylurea Compounds/pharmacokinetics ; Rats ; Rats, Sprague-Dawley ; Reproducibility of Results ; Tandem Mass Spectrometry/methods ; Tissue Distribution
    Chemical Substances 1-(3-((2-(dimethylamino)ethyl)carbamoyl)phenyl)-3-(4-(bis(2-chloroethyl)amino)phenyl)urea ; Antineoplastic Agents ; Nitrogen Mustard Compounds ; Phenylurea Compounds
    Language English
    Publishing date 2013-02-15
    Publishing country Netherlands
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1180823-8
    ISSN 1873-376X ; 0378-4347 ; 1570-0232 ; 1387-2273
    ISSN (online) 1873-376X
    ISSN 0378-4347 ; 1570-0232 ; 1387-2273
    DOI 10.1016/j.jchromb.2012.12.025
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Novel antitumor indolizino[6,7-b]indoles with multiple modes of action: DNA cross-linking and topoisomerase I and II inhibition.

    Chaniyara, Ravi / Tala, Satishkumar / Chen, Chi-Wei / Zang, Xiuguo / Kakadiya, Rajesh / Lin, Li-Fang / Chen, Ching-Huang / Chien, Shin-I / Chou, Ting-Chao / Tsai, Tung-Hu / Lee, Te-Chang / Shah, Anamik / Su, Tsann-Long

    Journal of medicinal chemistry

    2013  Volume 56, Issue 4, Page(s) 1544–1563

    Abstract: A series of bis(hydroxymethyl)indolizino[6,7-b]indoles and their bis(alkylcarbamates) were synthesized for antitumor studies. These agents were designed as hybrid molecules of β-carboline (topoisomerase inhibition moiety) and bis(hydroxymethyl)pyrrole ( ... ...

    Abstract A series of bis(hydroxymethyl)indolizino[6,7-b]indoles and their bis(alkylcarbamates) were synthesized for antitumor studies. These agents were designed as hybrid molecules of β-carboline (topoisomerase inhibition moiety) and bis(hydroxymethyl)pyrrole (DNA cross-linking moiety). The preliminary antitumor studies indicated that these agents exhibited significant cytotoxicity against a variety of human tumor cells in vitro. Treatment of human breast carcinoma MX-1 xenograft-bearing nude mice with compounds 18b and 28c achieved more than 99% tumor remission. We also observed that 18a displayed potent therapeutic efficacy against human lung adenocarcinoma A549 and colon cancer HT-29 xenografts. These results revealed that compound 18a was more potent than irinotecan against HT-29 cells and was as potent as irinotecan against A549 cells in xenograft models. Furthermore, we demonstrated that these derivatives possess multiple modes of action, such as induction of DNA cross-linking, inhibition of topoisomerase I and II, and cell-cycle arrest at the S-phase.
    MeSH term(s) Animals ; Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/chemistry ; Antineoplastic Agents/pharmacology ; Cell Line, Tumor ; Cross-Linking Reagents/chemical synthesis ; Cross-Linking Reagents/chemistry ; Cross-Linking Reagents/pharmacology ; DNA/metabolism ; Drug Screening Assays, Antitumor ; Humans ; Indoles/chemical synthesis ; Indoles/chemistry ; Indoles/pharmacology ; Indolizines/chemical synthesis ; Indolizines/chemistry ; Indolizines/pharmacology ; Intercalating Agents/chemical synthesis ; Intercalating Agents/chemistry ; Intercalating Agents/pharmacology ; Male ; Mice ; Mice, Nude ; Neoplasm Transplantation ; Rats ; S Phase Cell Cycle Checkpoints/drug effects ; Structure-Activity Relationship ; Topoisomerase I Inhibitors/chemical synthesis ; Topoisomerase I Inhibitors/chemistry ; Topoisomerase I Inhibitors/pharmacology ; Topoisomerase II Inhibitors/chemical synthesis ; Topoisomerase II Inhibitors/chemistry ; Topoisomerase II Inhibitors/pharmacology ; Transplantation, Heterologous
    Chemical Substances Antineoplastic Agents ; Cross-Linking Reagents ; Indoles ; Indolizines ; Intercalating Agents ; Topoisomerase I Inhibitors ; Topoisomerase II Inhibitors ; DNA (9007-49-2)
    Language English
    Publishing date 2013-02-28
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 218133-2
    ISSN 1520-4804 ; 0022-2623
    ISSN (online) 1520-4804
    ISSN 0022-2623
    DOI 10.1021/jm301788a
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Determination of tissue distribution of potent antitumor agent ureidomustin (BO-1055) by HPLC and its pharmacokinetic application in rats

    Chien, Shin-I. / Yen, Jiin-Cherng / Kakadiya, Rajesh / Chen, Ching-Huang / Lee, Te-Chang / Su, Tsann-Long / Tsai, Tung-Hu

    Journal of chromatography

    Volume v. 917-918

    Abstract: Ureidomustin hydrochloride (BO-1055) was designed as a water-soluble nitrogen-mustard, which exhibited potent anticancer activity and was selected as a candidate for preclinical studies. However, up to date, there is rarely an easy and economic method to ...

    Abstract Ureidomustin hydrochloride (BO-1055) was designed as a water-soluble nitrogen-mustard, which exhibited potent anticancer activity and was selected as a candidate for preclinical studies. However, up to date, there is rarely an easy and economic method to quantize ureidomustin in the biological samples. The aim of this study is to develop a simple yet valid quantization method to tackle this challenge. Here we present a combined high-performance liquid chromatography with photodiode array (HPLC-PDA) method in quantizing the ureidomustin in the plasma and various organs of Sprague-Dawley rats. The method was validated in terms of precision, accuracy, and extraction recovery. Furthermore, the established method was applied to study pharmacokinetics of ureidomustin in the rat's plasma and verified via a liquid chromatography tandem mass spectrometry (LC–MS/MS) method. Calibration curves of the plasma and organ samples were falling at the range between 0.5–50μg/mL and 0.1–50μg/mL (r²≥0.999 and CV≤±15%), respectively. The limits of detection (LOD) were 0.1μg/mL for plasma samples and 0.05μg/mL for organ samples, while the detection limits of quantification (LOQ) were 0.5μg/mL for plasma samples and 0.1μg/mL for organ samples. The average recovery of ureidomustin was about 83%. These results demonstrated a linear pharmacokinetic pattern at dosages of 10 and 30mg/kg. The pharmacokinetic data revealed that ureidomustin was best fitted to a two-compartment model with a rapid distribution phase and a slow elimination phase. Besides, after a short intravenous administration time at the dose of 10mg/kg, ureidomustin was found to be quickly distributed to all organs in rats, accumulated mainly in the kidney, and only a limited amount was detected in the brain.
    Keywords models ; tandem mass spectrometry ; kidneys ; intravenous injection ; detection limit ; antineoplastic agents ; tissue distribution ; rats ; pharmacokinetics ; high performance liquid chromatography ; brain
    Language English
    Document type Article
    ISSN 1570-0232
    Database AGRIS - International Information System for the Agricultural Sciences and Technology

    More links

    Kategorien

To top